Echinocandins - New antifungal drugs applied in medical practice;Echinokandyny - Nowe leki przeciwgrzybicze dostȩpne w praktyce medycznej

Mikologia Lekarska

Volumn 11, Issue 1, 2004, Pages 81-84

  Białynicki Birula, Rafał ^a   Baran, Eugeniusz ^a   Kołodziej, Tomasz ^a  

^a Kat/Klin Dermatol   (Poland)

Author keywords

Anidulafungin; Antifungal antibiotics; Antifungal drugs; Caspofungin; Echinocandin; Micafungin

Indexed keywords

AMPHOTERICIN B; ANIDULOFUNGIN; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; LIPOPEPTIDE; MICAFUNGIN; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; DRUG APPROVAL; DRUG MECHANISM; EUROPEAN UNION; FUNGICIDAL ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAPAN; MYCOSIS; REVIEW; UNITED STATES;

ASPERGILLUS; CANDIDA; MAMMALIA;

EID: 2642586637     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Kołodziej T., Białynicki-Birula R.: Lipidowe i liposomalne formy amfoterycyny B. Mikol. Lek., 2003, 10, 219-221.
2. Arathoon E.G.: Clinical efficacy of echinocandin antifungals. Curr. Opin. Infect. Dis., 2001, 14, 685-691.
3. Steinbach W.J., Stevens D.A., Denning D.W.: Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis., 2003, 37, 188-224.
4. Nowicki R.: Współczesne metody leczenia grzybic powierzchownych. [w:] Współczesne leczenie wybranych chorób skóry. red. A. Langner. Ośrodek Informacji Naukowej Polfa, Warszawa, 2002, 125-152.
5. Gupte M., Kulkarini P., Ganguli B.N.: Antifungal antibiotics. Appl. Microbiol. Biotechnol., 2002, 58, 46-57.
6. Georgopapadakou N.H.: Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert. Opin. Investig. Drugs., 2001, 10, 269-280.
7. Barrett D.: From natural products to clinically useful antifungals. Biochim. Biophys. Acta, 2002, 1587, 224-33.
8. Denning D.W.: Echinocandin antifungal drugs. Lancet., 2003, 362, 1142-1151.
9. Cornely O.A., Schmitz K., Aisenbrey S.: The first echinocandin: caspofungin. Mycoses, 2002, 45, 56-60.
10. Stone J.A., Holland S.D., Wickersham P.J., Sterrett A., Schwartz M., Bonfiglio C., Hesney M., Winchell G.A., Deutsch P.J., Greenberg H., Hunt T.L., Waldman S.A.: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents. Chemother., 2002, 46, 739-745.
11. Colombo A.L., Perfect J., DiNubile M., Bartlizal K., Motyl M., Hicks P., Lupinacci R., Sable C., Kartsonis N.: Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis., 2003, 22, 470-474.
12. Fromtling R.A.: Micafungin sodium (FK-463). Drugs Today (Barc). 2002, 38, 245-257.
13. Ullmann A.J.: Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin., 2003, 19, 263-271.
14. Macura B., Pawlik B.: Leczenie grzybic. [w:] Zarys mikologii lekarskiej. red. E. Baran. Volumed, Wrocław, 1998, 591-632.
15. Sutton D.A.: Laboratory evaluation of new antifungal agents against rare and refractory mycoses. Curr. Opin. Infect. Dis., 2002, 15, 575-582.
16. Kartsonis N., DiNubile M.J., Bartizal K., Hicks P.S., Ryan D., Sable C.: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune Defic. Syndr., 2002, 31, 183-187.